CS
MRTX

Credit Suisse’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Credit Suisse’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-59,533
Closed -$3.5M – 3069
2023
Q4 		$3.5M Sell
59,533
-485,093
-89% -$27.3M ﹤0.01% 1544
2023
Q3 		$23.7M Buy
544,626
+5,176
+1% +$185K 0.02% 594
2023
Q2 		$19.5M Buy
539,450
+16,083
+3% +$663K 0.02% 687
2023
Q1 		$19.5M Buy
523,367
+2,283
+0.4% +$103K 0.02% 675
2022
Q4 		$23.6M Buy
521,084
+78,711
+18% +$5.09M 0.03% 618
2022
Q3 		$30.9M Sell
442,373
-337
-0.1% -$24.9K 0.03% 532
2022
Q2 		$29.7M Buy
442,710
+1,123
+0.3% +$71.4K 0.03% 557
2022
Q1 		$36.3M Buy
441,587
+57,385
+15% +$5.87M 0.03% 569
2021
Q4 		$56.4M Sell
384,202
-12,425
-3% -$1.93M 0.03% 578
2021
Q3 		$70.2M Buy
396,627
+767
+0.2% +$123K 0.04% 498
2021
Q2 		$63.9M Buy
395,860
+53,614
+16% +$8.61M 0.03% 563
2021
Q1 		$58.6M Buy
342,246
+190,483
+126% +$37.7M 0.03% 635
2020
Q4 		$33.3M Sell
151,763
-39,489
-21% -$8.54M 0.02% 896
2020
Q3 		$31.8M Sell
191,252
-17,959
-9% -$2.46M 0.02% 804
2020
Q2 		$23.9M Buy
209,211
+58,846
+39% +$5.71M 0.02% 859
2020
Q1 		$11.6M Buy
150,365
+15,424
+11% +$1.38M 0.01% 1108
2019
Q4 		$17.4M Sell
134,941
-74,048
-35% -$7.14M 0.01% 1111
2019
Q3 		$16.3M Sell
208,989
-27,471
-12% -$2.58M 0.01% 1041
2019
Q2 		$24.4M Sell
236,460
-43,180
-15% -$3.36M 0.02% 817
2019
Q1 		$20.5M Sell
279,640
-179,663
-39% -$12.2M 0.02% 858
2018
Q4 		$19.5M Buy
459,303
+9,895
+2% +$394K 0.02% 807
2018
Q3 		$21.2M Buy
449,408
+424,202
+1,683% +$23.6M 0.02% 845
2018
Q2 		$1.24M Buy
25,206
+13,214
+110% +$499K ﹤0.01% 2847
2018
Q1 		$368K Buy
+11,992
New +$333K ﹤0.01% 3498
2017
Q3 		– Sell
-44,217
Closed -$161K – 4282
2017
Q2 		$161K Buy
+44,217
New +$169K ﹤0.01% 3659
2017
Q1 		– Sell
-23,639
Closed -$113K – 4131
2016
Q4 		$113K Buy
23,639
+1,581
+7% +$8.6K ﹤0.01% 3937
2016
Q3 		$145K Sell
22,058
-18,729
-46% -$99.7K ﹤0.01% 3872
2016
Q2 		$223K Buy
40,787
+26,191
+179% +$417K ﹤0.01% 3822
2016
Q1 		$312K Sell
14,596
-10,317
-41% -$231K ﹤0.01% 3488
2015
Q4 		$787K Sell
24,913
-5,625
-18% -$199K ﹤0.01% 3020
2015
Q3 		$1.05M Buy
+30,538
New +$923K ﹤0.01% 2782
2014
Q2 		– Sell
-13,000
Closed -$248K – 4838
2014
Q1 		$248K Buy
+13,000
New +$270K ﹤0.01% 4219

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Credit Suisse's MRTX Position: Q1 2024 in Review

Credit Suisse sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 59,533 shares — an estimated $3.5M sold.

Credit Suisse first reported a position in MRTX in Q1 2014 and held it in 32 quarters. The position peaked at $70.2M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Credit Suisse reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Credit Suisse sold 59,533 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.5M.
  • Credit Suisse first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 32 quarters.
  • Credit Suisse's Mirati Therapeutics, Inc. Common Stock position peaked at $70.2M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.